{
  "nctId": "NCT02442687",
  "briefTitle": "JKB-121 for the Treatment of Nonalcoholic Steatohepatitis",
  "officialTitle": "A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)",
  "protocolDocument": {
    "nctId": "NCT02442687",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2016-03-02",
    "uploadDate": "2018-08-23T22:58",
    "size": 713101,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02442687/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 65,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-08-01",
    "completionDate": "2017-09-24",
    "primaryCompletionDate": "2017-09-24",
    "firstSubmitDate": "2015-04-07",
    "firstPostDate": "2015-05-13"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Provision of written informed consent\n3. Biopsy-proven NASH within 12 months or at screening\n4. ALT \\> 40 U/L for women and \\> 60 U/L for men at screening and at least once in the previous 12 months.\n5. HBA1C of ≤ 9.0\n\nExclusion Criteria:\n\n1. Any chronic liver disease other than NASH\n2. Cirrhosis, as assessed clinically or histologically\n3. Presence of vascular liver disease\n4. BMI ≤ 25 kg/m2\n5. Excessive alcohol use (\\> 20 g/day) within the past 2 years\n6. AST or ALT \\> 250 U/L.\n7. Type 1 diabetes mellitus\n8. Bariatric surgery in the past 5 years.\n9. Weight gain of \\> 5% in past 6 months or \\> 10% change in past 12 months.\n10. Contraindication to MRI\n11. Inadequate venous access\n12. HIV antibody positive, hepatitis B surface antigen positive (HBsAg), or Hepatitis C virus (HCV) RNA positive.\n13. Receiving an elemental diet or parenteral nutrition\n14. Chronic pancreatitis or pancreatic insufficiency\n15. Any history of complications of cirrhosis\n16. Concurrent conditions:\n\n    * Inflammatory bowel disease\n    * Significant cardiac disease\n    * chronic infection or immune mediated disease\n    * Any malignant disease\n    * Prior solid organ transplant\n    * Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject participating or the interpretation of the study data.\n17. Concurrent medications which may treat NASH\n18. HbA1C \\> 9.0%\n19. Pregnancy or breastfeeding.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population)",
        "timeFrame": "Baseline to week 24"
      },
      {
        "measure": "Analysis of MRI-PDFF Change From Baseline to Week 12 (Per Protocol Population)",
        "timeFrame": "Baseline to Week 12"
      }
    ],
    "secondary": [
      {
        "measure": "Analysis of ALT Change From Baseline to Week 24 (Per Protocol Population)",
        "timeFrame": "Baseline to week 24"
      },
      {
        "measure": "Analysis of ALT Change From Baseline to Week 12 (Per Protocol Population)",
        "timeFrame": "Baseline to week 12"
      },
      {
        "measure": "Time to Remission (in Weeks)",
        "description": "Time to remission is the time in weeks from randomization to liver function remission, defined as two consecutive ALT values within normal range (\\<40 U/L) during the treatment period.",
        "timeFrame": "24 weeks"
      },
      {
        "measure": "Change in BMI (Body Mass Index)",
        "timeFrame": "Baseline, week 24"
      },
      {
        "measure": "Change in Hemoglobin A1C",
        "timeFrame": "Baseline, week 24"
      },
      {
        "measure": "Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)",
        "description": "HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. Optimal Range: 1.0 (0.5-1.4). Lower values represent a better outcome.",
        "timeFrame": "Baseline, week 24"
      },
      {
        "measure": "Percent Change in Cholesterol",
        "timeFrame": "Baseline, week 24"
      },
      {
        "measure": "Percent Change in Triglycerides",
        "timeFrame": "Baseline, week 24"
      },
      {
        "measure": "Percent Change in Low Density Lipoprotein (LDL) Cholesterol",
        "timeFrame": "Baseline, week 24"
      },
      {
        "measure": "Percent Change in High Density Lipoprotein (HDL)",
        "timeFrame": "Baseline, week 24"
      },
      {
        "measure": "Mean Serum Aspartate Aminotransferase (AST)",
        "timeFrame": "weeks 4, 8, 12, 16, 20, and 24"
      },
      {
        "measure": "Mean Serum Alanine Aminotransferase (ALT)",
        "timeFrame": "weeks 4, 8, 12, 16, 20, and 24"
      },
      {
        "measure": "Mean Serum Gamma-glutamyl Transpeptidase (GGT)",
        "timeFrame": "weeks 4, 8, 12, 16, 20, and 24"
      },
      {
        "measure": "Number of Subjects With ALT in Normal Range at Week 24",
        "description": "Normal range is \\<40 U/L",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Maximum Observed Concentrations (Cmax)",
        "timeFrame": "pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours"
      },
      {
        "measure": "Minimum Observed Concentration (Cmin)",
        "timeFrame": "pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours"
      },
      {
        "measure": "Area Under Concentration-time (AUC)",
        "timeFrame": "pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours"
      },
      {
        "measure": "Half-life",
        "timeFrame": "pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 18,
      "otherCount": 0,
      "totalCount": 20
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:10.508Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}